Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Phase 3positiveretatrutidePositive
AI Analysis
Summary
Eli Lilly's retatrutide demonstrated positive Phase 3 results in two obesity trials (TRIUMPH-2 and TRIUMPH-3), with significant weight loss and A1C improvements in patients with obesity and type 2 diabetes or cardiovascular disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
TRIUMPH-2: weight loss up to 49.6 lbs (20.8%) at 80 weeks in adults with obesity/overweight and type 2 diabetes. TRIUMPH-3: severe obesity with cardiovascular disease population showed significant improvements in weight and A1C.
Importance:8/10
Sentiment:
0.85
obesitytype 2 diabetescardiovascular diseaseweight lossGLP-1 receptor agonisttriple agonist
Related Companies
Read the original article
Published by PR Newswire Pharma on July 23, 2026 10:45 AM